Low-density lipoprotein and its effect on human blood platelets

被引:107
作者
Relou, IAM
Hackeng, CM
Akkerman, JWN
Malle, E
机构
[1] Univ Utrecht, Med Ctr, Lab Thrombosis & Haemostasis, Dept Hematol, NL-3508 GA Utrecht, Netherlands
[2] Univ Hosp Maastricht, Clin Chem Lab, NL-6202 AZ Maastricht, Netherlands
[3] Karl Franzens Univ Graz, Inst Med Biochem & Mol Biol, A-8010 Graz, Austria
关键词
thrombocyte-LDL interaction; aggregation; native and modified LDL; receptor; signaling pathway;
D O I
10.1007/s00018-003-2249-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Events leading to hyperactivity of human blood platelets are accompanied by an enhanced risk of atherosclerosis and arterial thrombosis. Lipoprotein disorders affect platelet functions, and hypersensitive platelets are observed in various stages of hyperlipidemia. Low-density lipoprotein (LDL), a circulating complex of lipids and proteins that is increased in hyper-cholesterolemia, enhances platelet function and increases sensitivity of platelets to several naturally occurring agonists. LDL sensitizes platelets via binding of apoB-100 to a receptor on the platelet membrane and via transfer of lipids to the platelet membrane. The receptor that mediates binding of LDL to the platelet and initiates subsequent intracellular signaling cascades has not yet been identified. Modification of native LDL generates a platelet-activating particle, and this interaction might contribute to the development of the atherosclerotic plaque. Lysophosphatidic acid is formed upon mild oxidation of LDL and is responsible for subsequent platelet activation induced by the modified LDL particle. Thus, LDL changes the functions of platelets via a broad spectrum of interactions.
引用
收藏
页码:961 / 971
页数:11
相关论文
共 115 条
  • [71] Effects of two different HMG-CoA reductase inhibitors on thromboxane production in type IIA hypercholesterolemia
    Milani, M
    Cimminiello, C
    Lorena, M
    Arpaia, G
    Soncini, M
    Bonfardeci, G
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 1996, 50 (6-7) : 269 - 274
  • [72] Milionis HJ, 1999, PLATELETS, V10, P357
  • [73] Peroxynitrite-induced tyrosine nitration and phosphorylation in human platelets
    Mondoro, TH
    Shafer, BC
    Vostal, JG
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 1997, 22 (06) : 1055 - 1063
  • [74] Naseem KM, 1997, PLATELETS, V8, P163, DOI 10.1080/09537109709169333
  • [75] The nitration of platelet cytosolic proteins during agonist-induced activation of platelets
    Naseem, KM
    Low, SY
    Sabetkar, M
    Bradley, NJ
    Khan, J
    Jacobs, M
    Bruckdorfer, KR
    [J]. FEBS LETTERS, 2000, 473 (01) : 119 - 122
  • [76] Nofer JR, 1997, CIRCULATION, V95, P1370
  • [77] INHIBITION OF THROMBOXANE BIOSYNTHESIS AND PLATELET-FUNCTION BY SIMVASTATIN IN TYPE IIA HYPERCHOLESTEROLEMIA
    NOTARBARTOLO, A
    DAVI, G
    AVERNA, M
    BARBAGALLO, CM
    GANCI, A
    GIAMMARRESI, C
    LAPLACA, FP
    PATRONO, C
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (02) : 247 - 251
  • [78] Effect of hypochlorite (HOCl)-modified low density lipoproteins and high density lipoproteins on platelet function
    Opper, C
    Schussler, G
    Sattler, W
    Malle, E
    [J]. PLATELETS, 1998, 9 (05) : 339 - 341
  • [79] Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets
    Osamah, H
    Mira, R
    Sorina, S
    Shlomo, K
    Michael, A
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (01) : 77 - 83
  • [80] LDL BINDING-SITES ON PLATELETS DIFFER FROM THE CLASSICAL RECEPTOR OF NUCLEATED CELLS
    PEDRENO, J
    DECASTELLARNAU, C
    CULLARE, C
    SANCHEZ, J
    GOMEZGERIQUE, J
    ORDONEZLLANOS, J
    GONZALEZSASTRE, F
    [J]. ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (11): : 1353 - 1362